01 December 2006
Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: A review
Giuliano Rizzardini, Amedeo CapettiMed Sci Monit 2006; 12(12): RA269-276 :: ID: 469713
Abstract
The major trials conducted on treatment simplifi cation included large portions of patients who had previously received monotherapy or dual therapy and were likely to have relevant mutations of resistance at baseline. These studies concluded that simplifi cation was safe (especially when this
population was excluded), with some additional risk of viral failure for subjects simplifi ed to abacavir- based regimens. On the other hand, induction-maintenance studies and other studies which involved only patients who had started HAART as the fi rst-line showed that simplifi cation to abacavir
was as safe as continuation of the original regimen and better accepted by the patients. The largest randomized studies of simplifi cation that allowed extrapolation of data on the population of subjects who had never received suboptimal therapy were reviewed. Four studies failed to show signifi cant differences in effi cacy between treatment arms, while two detected signifi cant differences in favor of the continuation arms. Simplifi cation to abacavir led to signifi cant decreases in cholesterol and triglyceride levels and to slight improvements in quality of life. No variations in body shape were detected, although the duration was probably insuffi cient and most studies
did not involve adequate technology (i.e. DEXA, CT). Other, smaller studies are also presented in the review, selected for their particular design or analysis, which may contribute to a better understanding of the setting in which simplifi cation may be a feasible option. Choosing the adequate timing and the correct patient characteristics, simplifi cation to abacavirbased
regimens is safe and prevents metabolic consequences of therapy.
Keywords: Dideoxynucleosides - adverse effects, Antiretroviral Therapy, Highly Active, Anti-HIV Agents - adverse effects, Drug Resistance, Viral - genetics, Drug Therapy, Combination, Drug Tolerance, HIV Infections - drug therapy, HIV-1 - genetics, Multicenter Studies as Topic, Mutation, Safety
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952